The Determinants of Research and Development Investment in the Pharmaceutical Industry: Focus on Financial Structures

다국어 초록 (Multilingual Abstract)

Objectives: This study analyzes the influence of the financial structure of pharmaceutical companies on R&D investment to create a next-generation profit source or develop relatively cost-effective drugs to maximize enterprise value. Methods: The period of the empirical analysis is from 2000 to 2012. Financial statements and comments in general and internal transactions were extracted from TS-2000 of the Korea Listed Company Association (KLCA), and data related to stock price is extracted from KISVALUE-Ⅲ of NICE Information Service Co., Ltd. Stata 12.0 was used as the statistical package for panel analysis. Results: The current ratio had a positive influence on R&D investment, the debt ratio had a negative influence on R&D investment, and return on investment and net sales growth rate did not have a significant influence on R&D investment. Conclusion: It was found in this study that the higher liquidity ratio, the greater the R&D investment. The stability of pharmaceutical companies has a negative influence on R&D investment. This finding is consistent with the prediction that if a company faces a financial risk, it will be passive in R&D investment due to its financial difficulties.

참고문헌 (Reference)

1 구재운, "한국 제조기업 투자의 금융요인에 대한 실증분석:자금조달순위가설과 잉여현금흐름가설을 중심으로" 한국금융학회 12 (12): 29-54, 2007

2 이경민, "우리나라 제약산업의 연구개발(R&D)투자가 기업성과에 미치는 영향" 한국전문경영인학회 10 (10): 81-100, 2007

3 Arrow K., "The rate and direction of inventive activity: Economic and social factors" Princeton 609-626, 1962

4 Grabowski HG, "The distribution of sales revenues from pharmaceutical innovation" 18 (18): 21-32, 2000

5 Modigliani F, "The cost of capital, corporation finance and the theory of investment" 48 (48): 261-297, 1958

6 Baysinger B, "The composition of boards of directors and strategic control: effects on corporate strategy" 15 (15): 72-87, 1990

7 Kamien MI, "Self-Financing of an R and D Project" 68 (68): 252-261, 1978

8 Himmelberg CP, "R & D and internal finance: a panel study of small firms in high-tech industries" 76 (76): 38-51, 1994

9 Stulz R., "Managerial discretion and optimal financing policies" 26 (26): 3-27, 1990

10 Shleifer A, "Management entrenchment: the case of manager-specific investments" 25 (25): 123-139, 1989

11 Hall BH, "Investment and research and development at the firm level: does the source of financing matter?" National Bureau of Economic Research 1992

12 Kochhar R, "Institutional investors and firm innovation: A test of competing hypotheses" 17 (17): 73-84, 1996

13 Bhattacharya S, "Innovation and communication:signaling with partial disclosure" 50 (50): 331-346, 1983

14 Pindado J, "How do firm characteristics influence the relationship between R&D and firm value?" 39 (39): 757-782, 2010

15 Stein JC., "Handbook of the economics of finance" Elsevier 111-165, 2003

16 Fazzari S, "Financing constraints and corporate investment" National Bureau of Economic Research Cambridge 1988

17 Vernon JA, "Examining the link between price regulation and pharmaceutical R&D investment" 14 (14): 1-16, 2005

18 Stiglitz JE, "Credit rationing in markets with imperfect information" 71 (71): 393-410, 1981

19 Bhagat S, "Corporate research & development investments international comparisons" 19 (19): 443-470, 1995

20 Myers SC, "Corporate financing and investment decisions when firms have information that investors do not have" 13 (13): 187-221, 1984

21 Hoskisson RE, "Conflicting voices: the effects of institutional ownership heterogeneity and internal governance on corporate innovation strategies" 45 (45): 697-716, 2002

22 Jensen MC, "Agency costs of free cash flow, corporate finance, and takeovers" 76 (76): 323-329, 1986